JPET # 142711 1 Anti-Ccl2 Spiegelmer permits 75% dose reduction of cyclophosphamide to control diffuse proliferative lupus nephritis and pneumonitis in MRL-Fas(lpr) mice Onkar Kulkarni, Dirk Eulberg, Norma Selve, Stefan Zöllner, Ramanjaneyulu Allam, Rahul D. Pawar, Stephanie Pfeiffer, Stephan Segerer, Sven Klussmann, Hans-Joachim Anders Nephrological Center, Medical Policlinic, Ludwig-Maximilians-University, Munich, Germany (O.K., R.A., R.D.P. ,S.P. ,S.S., H.J.A.) NOXXON Pharma AG, Berlin, Germany (D.E., N.S., S.Z., S.K.) JPET Fast Forward. Published on November 7, 2008 as DOI:10.1124/jpet.108.142711 Copyright 2008 by the American Society for Pharmacology and Experimental Therapeutics. This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on November 7, 2008 as DOI: 10.1124/jpet.108.142711 at ASPET Journals on December 5, 2021 jpet.aspetjournals.org Downloaded from